1
|
Abbaszadeh M, Ozanick E, Magen N, Darrow D, Yan X, Grissom N, Herman AB, Ebitz BR. Individual differences in sequential decision-making. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2025:2025.04.04.647306. [PMID: 40236038 PMCID: PMC11996512 DOI: 10.1101/2025.04.04.647306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 04/17/2025]
Abstract
1People differ widely in how they make decisions in uncertain environments. While many studies leverage this variability to measure differences in specific cognitive processes and parameters, the key dimension(s) of individual variability in uncertain decision-making tasks has not been identified. Here, we analyzed behavioral data from 1001 participants performing a restless three-armed bandit task, where reward probabilities fluctuated unpredictably over time. Using a novel analytical approach that controlled for the stochasticity in this tasks, we identified a dominant nonlinear axis of individual variability. We found that this primary axis of variability was strongly and selectively correlated with the probability of exploration, as inferred by latent state modeling. This suggests that the major factor shaping individual differences in bandit task performance is the tendency to explore (versus exploit), rather than personality characteristics, reinforcement learning model parameters, or low-level strategies. Certain demographic characteristics also predicted variance along this principle axis: participants at the exploratory end tended to be younger than participants at the exploitative end, and self-identified men were overrepresented at both extremes. Together, these findings offer a principled framework for understanding individual differences in task behavior while highlighting the cognitive and demographic factors that shape individual differences in decision-making under uncertainty.
Collapse
|
2
|
Ruehr L, Hoffmann K, May E, Münch ML, Schlögl H, Sacher J. Estrogens and human brain networks: A systematic review of structural and functional neuroimaging studies. Front Neuroendocrinol 2025; 77:101174. [PMID: 39733923 DOI: 10.1016/j.yfrne.2024.101174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2024] [Revised: 10/23/2024] [Accepted: 12/22/2024] [Indexed: 12/31/2024]
Abstract
Estrogen fluctuations during the menstrual cycle, puberty, postpartum, or in the menopausal transition are associated with cognitive, affective, and behavioral effects. Additionally, estrogens are essential in hormonal contraception, menopausal hormone therapy, or gender-affirming hormone therapy. This systematic review summarizes findings on the role of estrogens for structure, function, and connectivity of human brain networks. We searched PubMed, Web of Science, and ScienceDirect for neuroimaging articles assessing estrogens published since 2008. We included 54 studies (N = 2,494 participants) on endogenous estrogen, and 28 studies (N = 1,740 participants) on exogenous estrogen conditions. Estrogen-related changes were reported for emotion, reward, memory, and resting-state networks, and in regional white and gray matter, with a particular neural plasticity in the hippocampus and amygdala. By examining study designs, imaging measures, and analysis methods, this review highlights the role of neuroimaging in advancing neuroendocrine and neurocognitive research, particularly promoting brain health for women and individuals with ovaries.
Collapse
Affiliation(s)
- Livia Ruehr
- Center for Integrative Women's Health and Gender Medicine, Medical Faculty and University of Leipzig Medical Center, Leipzig, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103 Leipzig, Germany; Max Planck School of Cognition, Stephanstraße 1A, 04103 Leipzig, Germany; Clinic of Cognitive Neurology, University of Leipzig Medical Center, Liebigstraße 16, 04103 Leipzig, Germany.
| | - Kim Hoffmann
- Center for Integrative Women's Health and Gender Medicine, Medical Faculty and University of Leipzig Medical Center, Leipzig, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103 Leipzig, Germany; Clinic of Cognitive Neurology, University of Leipzig Medical Center, Liebigstraße 16, 04103 Leipzig, Germany; Humboldt-Universität zu Berlin, Berlin School of Mind and Brain, Unter den Linden 6, 10099 Berlin, Germany.
| | - Emily May
- Center for Integrative Women's Health and Gender Medicine, Medical Faculty and University of Leipzig Medical Center, Leipzig, Germany; Max Planck School of Cognition, Stephanstraße 1A, 04103 Leipzig, Germany; Clinic of Cognitive Neurology, University of Leipzig Medical Center, Liebigstraße 16, 04103 Leipzig, Germany.
| | - Marie Luise Münch
- Leipzig Reproductive Health Research Center, Liebigstraße 20A, 04103 Leipzig, Germany.
| | - Haiko Schlögl
- Department of Endocrinology, Nephrology, Rheumatology, Division of Endocrinology, University of Leipzig Medical Center, Liebigstraße 20, 04103 Leipzig, Germany; Helmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University of Leipzig Medical Center, Philipp-Rosenthal-Straße 27, 04103 Leipzig, Germany.
| | - Julia Sacher
- Center for Integrative Women's Health and Gender Medicine, Medical Faculty and University of Leipzig Medical Center, Leipzig, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstraße 1A, 04103 Leipzig, Germany; Max Planck School of Cognition, Stephanstraße 1A, 04103 Leipzig, Germany; Clinic of Cognitive Neurology, University of Leipzig Medical Center, Liebigstraße 16, 04103 Leipzig, Germany; Department of Endocrinology, Nephrology, Rheumatology, Division of Endocrinology, University of Leipzig Medical Center, Liebigstraße 20, 04103 Leipzig, Germany.
| |
Collapse
|
3
|
Auer MK, Joue G, Biedermann SV, Sommer T, Fuss J. The effect of short-term increase of estradiol levels on sexual desire and orgasm frequency in women and men: A double-blind, randomized, placebo-controlled trial. Psychoneuroendocrinology 2024; 160:106682. [PMID: 38056372 DOI: 10.1016/j.psyneuen.2023.106682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2022] [Revised: 11/15/2023] [Accepted: 11/19/2023] [Indexed: 12/08/2023]
Abstract
Estradiol (E2) has been implicated in sexual functioning in both sexes. E2 levels change distinctively over the menstrual cycle, peaking around ovulation. Data on short-term effects of fluctuating E2 levels on sexual desire are however sparse and mostly based on observational studies. To fill this gap, we ran a double-blind, randomized, placebo-controlled study (N = 126) to investigate the effects of a short-term increase in E2 on sexual desire and orgasm frequency in healthy, young men and women. Circulating E2 levels were elevated through estradiol valerate (E2V) administered over two consecutive days to simulate the rise in E2 levels around ovulation. E2V had no effect on orgasm frequency and only minor effects on sexual desire. On average, the administered E2V dampened change in sexual desire compared to untreated participants with comparable baseline sexual desire in such a way that sexual desire was slightly reduced even in those with higher baseline sexual desire. These findings suggest that short-term increases in E2 have little effect on sexual function and are unlikely to explain the increase in sexual desire around ovulation.
Collapse
Affiliation(s)
- Matthias K Auer
- Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro, and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany
| | - Gina Joue
- Institute of Systems Neuroscience, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Sarah V Biedermann
- Social and Emotional Neuroscience, Department of Psychiatry and Psychotherapy, Center of Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Tobias Sommer
- Institute of Systems Neuroscience, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Johannes Fuss
- Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro, and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany.
| |
Collapse
|
4
|
Rune GM, Joue G, Sommer T. Effects of 24-hour oral estradiol-valerate administration on hormone levels in men and pre-menopausal women. Psychoneuroendocrinology 2023; 156:106320. [PMID: 37307791 DOI: 10.1016/j.psyneuen.2023.106320] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 06/06/2023] [Accepted: 06/07/2023] [Indexed: 06/14/2023]
Abstract
In order to translate the findings from the vast animal literature on the effect of 17β-estradiol (E2) on brain and behavior to humans, a placebo-controlled pharmacological enhancement of E2 levels for at least 24 h is necessary. However, an exogenous increase in E2 for such a prolonged period might affect the endogenous secretion of other (neuroactive) hormones. Such effects would be of relevance for the interpretation of the effects of this pharmacological regimen on cognition and its neural correlates as well as be of basic scientific interest. We therefore administered a double dose of 12 mg of estradiol-valerate (E2V) to men and of 8 mg to naturally cycling women in their low-hormone phase, and assessed the concentration of two steroids critical to hormone regulation: follicle stimulating hormone (FSH) and luteinizing hormone (LH). We also assessed any changes in concentration of the neuroactive hormones progesterone (P4), testosterone (TST), dihydrotestosterone (DHT) and immune-like growth factor 1 (IGF-1). This regimen resulted in similar E2 levels in both sexes (saliva and serum). FSH and LH levels in both sexes were down-regulated to the same degree. P4 concentration decreased in both sexes only in serum but not saliva. TST and DHT levels dropped only in men whereas sex-hormone binding globulin was not affected. Finally, the concentration of IGF-1 decreased in both sexes. Based on previous studies on the effects of these neuroactive hormones, only the degree of downregulation of TST and DHT levels in men might have an impact on brain and behavior, which should be considered when interpreting the effects of the presented E2V regimes.
Collapse
Affiliation(s)
- Gabriele M Rune
- Institute of Cell Biology and Neurobiology, Charité Anatomy, Charitéplatz 1, 10117 Berlin, Germany
| | - Gina Joue
- Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20248 Hamburg, Germany
| | - Tobias Sommer
- Institute of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20248 Hamburg, Germany.
| |
Collapse
|